Bone Morphogenetic Protein 2 Plus Leukocyte and Platelet-Rich Fibrin for the Treatment of MRONJ

J Craniofac Surg. 2023 Jun 1;34(4):e338-e341. doi: 10.1097/SCS.0000000000009059. Epub 2022 Oct 11.

Abstract

Leukocyte and platelet-rich fibrin is known to contain high concentrations of growth factors and when associated with rhBMP-2, it may increase bone remodeling due to its osteoinductive property. The aim of this case is to report the outcome of surgical treatment of medication-related osteonecrosis of the jaw with prototype plate installation and the use of leukocyte and platelet-rich fibrin in association with rhBMP-2 in a 78-year-old female patient under therapy with alendronate. The present Studies describes that the combination of this treatment presented complete healing of osteonecrosis and represents a promising treatment option to be used for medication-related osteonecrosis of the jaw.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / surgery
  • Bone Density Conservation Agents*
  • Bone Morphogenetic Protein 2 / therapeutic use
  • Female
  • Humans
  • Leukocytes
  • Platelet-Rich Fibrin*
  • Wound Healing

Substances

  • Bone Morphogenetic Protein 2
  • Bone Density Conservation Agents